Stevanato Group S.p.A.

NYSE:STVN

Medical - Instruments & Supplies

Healthcare
$15.36 +3.90%

+$0.67 today

Market cap
$4.20B
Beta
0.78
P/E (TTM)
29.9
EPS (TTM)
$0.52
Dividend yield
0.35%
52W Low $12.89High $28.00

Volume 0.61M

Average 0.52M

STVN Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Stevanato Group S.p.A.NYSE: STVN

Revenue · Q2 FY2026 · quarter ended Jun 2026

Revenue grows in line with its trailing trend

Q2 FY2026 revenue of €302M rose 7.8% year over year, ahead of the +6.7% change in trailing-twelve-month revenue. Sequentially, it rose 10.4% from the prior quarter. Over 3 fiscal years it compounded at +5.0% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 10 analysts of €1.26B (+10.2%) for the fiscal year ending Dec 2026, a step up from the +3.2% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
€302M+10.4% QoQ
Last fiscal yearDec 2025
€1.14B+3.2% YoY
LTMJun 2026
€1.22B+6.7% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+7.8%+7.3%-0.6 pp
1 year+3.2%+10.2%+6.9 pp
3-year CAGR+5.0%+6.8%+1.8 pp
5-year CAGR+9.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

EUR · from the income statement

Latest · FY2025
1.14B EUR
Year-over-year change
+3.2%
4-year CAGR
+7.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How STVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +6.7% is the 6th highest of 10, against a peer median of +8.8%.
  • Over three fiscal years its annual growth of +5.0% compares with a peer median of +5.8%.
STVN Competitors
Revenue for STVN and competitors
Company Period LTM YoY 3-year CAGR
BTSGBrightSpring Health Services, Inc. Common StockLTM Sep 2026$15.25B USD+22.9%+18.7%
AVTRAvantor, Inc.LTM Jun 2026$6.56B USD-1.6%-4.5%
BLCOBausch + Lomb CorporationLTM Jun 2026$5.32B USD+8.8%+10.6%
ATRAptarGroup, Inc.LTM Jun 2026$3.93B USD+8.9%+4.4%
TFXTeleflex IncorporatedLTM Jun 2026$2.6B USD-14.5%-10.6%
CHEChemed CorporationLTM Jun 2026$2.6B USD+3.3%+5.8%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$1.61B USD+9.2%+9.6%
MASIMasimo CorporationLTM Apr 2026$1.56B USD-14.4%-9.1%
STVNStevanato Group S.p.A.LTM Jun 2026€1.22B EUR+6.7%+5.0%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$776.57M USD+56.9%+133.7%
NUVLNuvalent, Inc.LTM Mar 2026$0 USD——
Peer median (excluding STVN) —+8.8%+5.8%

Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue843.92M983.68M1.09B1.1B1.14B
Cost of Revenue578.52M663.88M745.46M801.72M809.15M
Gross Profit265.41M319.8M339.89M302.32M330.33M
Gross Margin31.4%32.5%31.3%27.4%29.0%
Research & Development29.62M34.39M35.67M31.67M24.4M
Selling, General & Admin82.95M111.83M113.92M118.6M122.85M
Operating Expenses103.18M127.37M139.17M141.18M147.25M
Depreciation & Amortization56.38M64.82M78.48M80.65M88.57M
EBITDA226.93M256.4M272.35M247.8M292.01M
EBITDA Margin26.9%26.1%25.1%22.4%25.6%
Operating Income162.23M192.43M200.72M161.14M183.08M
Operating Margin19.2%19.6%18.5%14.6%16.1%
Interest Income548K648K792K1.72M12.49M
Interest Expense4.87M3.94M4.32M6.86M21.8M
Other Income / Expenses3.45M(4.79M)(11.17M)(854K)(1.44M)
Income Before Tax165.67M187.64M189.55M160.29M181.64M
Pre-Tax Margin19.6%19.1%17.5%14.5%15.9%
Income Tax Expense31.4M44.63M43.86M42.52M47.35M
Net Income134.32M142.85M145.63M117.78M134.28M
Net Margin15.9%14.5%13.4%10.7%11.8%
EPS (Basic)0.530.530.550.430.49
EPS (Diluted)0.530.530.550.430.49
Weighted Avg Shares264.7M264.7M264.95M272.87M273M
Weighted Avg Shares (Diluted)264.7M264.7M264.98M272.88M273M

Stevanato Group S.p.A.

NYSE:STVN

Intrinsic Alpha fair value

Locked

Current Price

$15.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.